A case of successful pembrolizumab monotherapy in a patient with advanced lung adenocarcinoma: Use of multiple biomarkers in combination for clinical practice

Clinical treatment is challenging for elderly patients with lung cancer who cannot tolerate chemotherapy, do not have cancer driver genes, and have low expression of PD-L1. Since these patients are usually excluded from clinical studies, evidence-based medicine supporting the use of immunotherapy is...

Full description

Bibliographic Details

Published in:	Open Medicine
Main Authors:	Guo Hanfei, Qian Lei, Chen Xiao, Zhao Yuguang, Song Wei, Guan Yanjie, Cui Jiuwei
Format:	Article
Language:	English
Published:	De Gruyter 2021-12-01
Subjects:	immune checkpoint inhibitors prognostic marker hyperprogressive disease
Online Access:	https://doi.org/10.1515/med-2021-0404